Pentatropis capensis

Other Names

Asclepias microphylla Roth ex Schult.Colostephanus capensis (L.f.) Harv.Cynanchum acuminatum Thunb.Cynanchum capense L.f.Cynanchum capense R.Br.Cynanchum capense Sieber ex Decne.Cynoctonum capense (L.f.) E.Mey.DodhiyalHemidesmus cordatus (Poir.) Schult.KākanāsāKakanasaKakanasikaKākanāsikāKukka BachchataayParparamPentatropis capensis (L.f.) BullockPentatropis microphylla (Roth ex Schult.) Wight & Arn.Pentatropis microphylla Wall.Periploca cordata Poir.Small-leaf MilkweedSurjavelUppilankodiVincetoxicum capense (L.f.) KuntzeVincetoxicum capense (L.f.) Schltr.

Synopsis

Pentatropis capensis (L.f.) Bullock

1. Identity, Botanical Classification, and Natural Source

1.1 Accepted Name and Taxonomy

Pentatropis capensis (L.f.) Bullock is the accepted scientific name for this species. According to NCBI Taxonomy, its full classification is: Kingdom Viridiplantae, Phylum Streptophyta, Class Magnoliopsida, Order Gentianales, Family Apocynaceae, Genus Pentatropis. The genus Pentatropis was first described in 1834 and is native to Africa and southern Asia. The species epithet capensis refers to the Cape region of southern Africa, reflecting the broad geographic range recognized when the species was originally circumscribed. The current binomial combination was formally established by Bullock, published in the Kew Bulletin (volume 10, number 2, page 284) on 12 September 1955, with the family entry recorded as Asclepiadaceae (now subsumed within Apocynaceae).

Pentatropis capensis (L.f.) Bullock is a member of the Apocynaceae family and is a slender, twining herb traditionally used in Ayurveda and Siddha systems of medicine. According to Plants of the World Online (Kew Science), the native range of this species is the Indian Subcontinent; it is a climbing subshrub that grows primarily in the seasonally dry tropical biome. The distribution range documented by Kew includes Bangladesh, India, Pakistan, and Sri Lanka, as well as Vietnam.

1.2 Synonymy

The species has accumulated a substantial synonymy over its taxonomic history. Accepted synonyms include Asclepias microphylla Roth ex Schult., Colostephanus capensis (L.f.) Harv., Cynanchum capense L.f., Cynanchum capense R. Br., Cynanchum capense Sieber ex Decne., Cynoctonum capense (L.f.) E. Mey., Pentatropis microphylla Wall. (nom. nud.), Pentatropis microphylla (Roth ex Schult.) Wight & Arn., Vincetoxicum capense (L.f.) Kuntze, and Vincetoxicum capense (L.f.) Schltr. Botanical references to this plant date back to Linnaeus's son, with early documentation appearing in Supplementum Plantarum (1782), the Memoirs of the Wernerian Natural History Society (1810), and the Systema Vegetabilium (1820).

The IMPPAT Indian phytochemical database registers the plant under synonymous names including Pentatropis microphylla, noting its use across the systems of Ayurveda, Siddha, and Sowa Rigpa.

1.3 Common Names

The plant carries different common names across linguistic and traditional contexts. In Ayurveda it is identified as Kakanasa and is mentioned in classical texts for its therapeutic significance; the Siddha system refers to it as Uppilankodi, where it is used in the preparation of gold and silver parpams (bhasma formulations). In Tamil, it is called uppilian kodi. The plant is also called Kākanāsikā in Ayurvedic works. Folklore practitioners in Andhra Pradesh refer to it under the Telugu name Kukka Bachchataay. The informal English common name "small-leaf milkweed" is also used, reflecting the plant's former placement in the milkweed subfamily Asclepiadoideae.

1.4 Morphology and Habitat

Morphologically, the plant is characterized by ovate, semi-succulent leaves, extra-axillary inflorescences, and purplish flowers with a distinctive corona. Members of the genus are characterized as slender, twining herbs or undershrubs with semi-succulent leaves and small purplish flowers; the flowers possess a rotate corolla and a corona made up of five erect, laterally compressed lobes, each bearing an upcurved spur at the base. It is native to the Indian subcontinent, especially in arid and semi-arid regions.

The pharmacognostic literature has subjected the plant to systematic morphological documentation. Pharmacognostic work on P. capensis has highlighted its botanical parameters, particularly microscopic standards; features least affected by environmental stress were given emphasis, including cross-sectional structure of the midrib and lamina, surface features of the epidermis and stomata, venation pattern of the lamina, cross-sectional outline and vascular pattern of the petiole, and structure of tissues in the stem and root.

1.5 Preparation Forms

As a traditional plant drug, P. capensis is prepared and used in a variety of forms. Ethnomedicinal uses include taking warm leaf juice as nasal drops to alleviate headache, running nose, and body ache; leaves of this plant are boiled with coconut oil and externally used in cuts and wounds, and are also considered effective in upper respiratory infection. In classical Indian pharmaceutical preparations, the plant is incorporated into multi-ingredient polyherbal compounds. It is included as an ingredient in classical formulations such as Chyavanprasha, Trayaushanadi Ghrita, and therapies for conditions like Apasmara (epilepsy), Yoni Roga (gynaecological disorders), Kasa (cough), Kustha (skin diseases), and in Anuvasana Basti procedures. In contemporary laboratory research, extracts have been prepared using aqueous, methanolic, ethanolic, ethyl acetate, hexane, and chloroform solvents, reflecting the range of phytochemical classes targeted.

2. Traditional and Historical Use

2.1 Ayurvedic Tradition

Acharya Charaka mentioned Kakanasa in the Madhura Skandha of Vimana Sthana (chapter 8), highlighting its nourishing qualities. Sushruta briefly mentions it in Anuvasana Vasti (medicated oil enema), while Ashtanga Hridaya describes its use in treating Guhya Roga (genital disorders), as well as in Chyavanprash and Anuvasana Vasti Karma. These textual references place the plant's formal recognition in Ayurveda at least within the classical period of Sanskrit medical literature, spanning roughly the first millennium CE.

Various Ayurvedic lexicons highlight its properties as an emetic, rasayana (rejuvenator), balya (strength promoter), palitapaha (anti-greying), analgesic, and anti-inflammatory. It is considered beneficial in managing Shotha (inflammation), Raktavikara (blood disorders), Shvitra (vitiligo), Kustha (skin diseases), and Gulma (abdominal tumours).

2.2 Siddha Tradition

The Siddha system refers to it as Uppilankodi, where it is used in the preparation of gold and silver parpams (bhasma formulations). Bhasma preparations involve high-temperature calcination processes in which the plant material is used as a processing agent or co-ingredient, a practice characteristic of Siddha iatrochemistry in South India.

2.3 Folk and Tribal Ethnomedicine

Tribal medicine practices, particularly those of tribal people in South India, involve the use of the leaves of Pentatropis capensis, which are heated and used as nasal drops to alleviate headaches, running noses, and body pain. Among folklore practitioners, the whole plant is traditionally used as an antifungal, antiseptic, coolant, and in the treatment of various skin ailments; it is commonly referred to as Kukka bachchataay, used to treat ailments such as headache, body ache, running nose, and upper respiratory infection.

The plant is included as an ingredient in classical formulations for conditions including Apasmara (epilepsy), Yoni Roga (gynaecological disorders), and Kasa (cough). Ethnobotanical records indicate its application in the treatment of various ailments including inflammation, skin diseases, epilepsy (Apasmara), and gynecological disorders.

3. Phytochemical Constituents and Proposed Mechanisms of Action

3.1 General Phytochemical Profile

Members of the Asclepiadaceae (now Apocynaceae) taxon, to which P. capensis belongs, possess many bioactive constituents such as triterpenes, alkaloids, cyanogenetic glycoside, saponins, tannins, and cyclitols. Preliminary phytochemical screening on P. capensis itself has confirmed a broadly consistent profile. Preliminary phytochemical screening has confirmed the presence of flavonoids, alkaloids, saponins, terpenoids, steroids, and phenolic compounds, each contributing to the plant's pharmacological profile.

Investigation of P. capensis also revealed positive results for the presence of steroids, flavonoids, tannins and glycosides.

3.2 Named Isolated Compounds

A small number of named compounds have been directly identified from the plant. A literature survey confirmed the presence of the following bioactive phytochemical constituents in P. capensis: n-octacosanol, α-amyrin, friedelin, β-sitosterol, and salicylic acid.

More recent analytical work using GC-MS and LC-MS has expanded the identified chemical inventory. GC-MS and LC-MS analyses identified key bioactive compounds; molecular docking revealed strong binding affinities of major constituents, particularly octadecanedioic acid, cyclohexane derivatives, and n-octacosanol, toward the colorectal cancer target DCAF1/VprBP (3WA0).

A GC-MS analysis identified a diverse array of 28 compounds, with major constituents including 1,6-anhydro-α-D-glucopyranose and propane, 1,1,3-triethoxy-, indicating significant bioactivity.

3.3 Quantitative Phytochemical Data

A 2026 study in Chemistry & Biodiversity compared three solvent fractions of leaf extracts. The study investigated the phytochemical composition and biological activities of methanolic, ethyl acetate, and hexane leaf extracts; the methanolic extract showed the highest extractive yield as well as the greatest phenolic (16.5 mg GAE/g) and flavonoid (20 mg QE/g) contents.

3.4 Proposed Mechanisms of Action

Flavonoids and phenolics are primarily associated with strong antioxidant activity, while alkaloids and saponins are known for antimicrobial and anti-inflammatory effects. The triterpene constituent α-amyrin and the sterol β-sitosterol, both identified in P. capensis, are widely recognized in the phytopharmacological literature as contributors to anti-inflammatory activity, generally attributed to inhibition of arachidonic acid metabolism and modulation of pro-inflammatory enzyme pathways, though such specific mechanistic work has not been published directly for P. capensis at the human or isolated-enzyme level to date.

Friedelin, another identified constituent, is a pentacyclic triterpene with documented biological activities in related plant studies. n-Octacosanol, a long-chain primary aliphatic alcohol, has been studied in other plant contexts for effects on the nervous system and lipid metabolism, though again, specific mechanistic pathway elucidation within P. capensis research remains preliminary and largely inferential from compound class.

4. Scientific Evidence by Area of Use

Important caveat: As of 2026, there are no published randomized controlled trials (RCTs) or clinical studies in human subjects for P. capensis. All pharmacological evidence is derived from in vitro (cell-culture or biochemical assay) and in vivo animal experiments, or from computational (in silico) modelling. The scientific evidence base must therefore be characterized as preliminary and preclinical throughout this section. P. capensis is traditionally used to treat various ailments; however, it lacks systematic scientific validation.

4.1 Analgesic and Anti-Inflammatory Activity

The most rigorous preclinical pharmacology published on P. capensis concerns its analgesic and anti-inflammatory potential. A peer-reviewed study published in the journal Ancient Science of Life (PubMed/PMC indexed, 2014) directly evaluated aqueous leaf extract. The study investigated the analgesic and anti-inflammatory effects of aqueous extract of P. capensis leaves (AEPC) in rats; AEPC was assessed for analgesic effect through the radiant heat tail-flick model and anti-inflammatory effect through the carrageenan-induced paw edema model in Wistar strain albino rats.

P. capensis leaves aqueous extract showed significant (P < 0.001) increase in the duration of latency of tail flick response at dose levels of 450 mg/kg, p.o.; the observed effects were comparable with the standard drug-treated group, thus demonstrating effective central analgesic and acute anti-inflammatory potentials of the P. capensis leaves aqueous extract. The observations substantiate its folklore use as an analgesic and anti-inflammatory.

Evidence strength: This is an animal study (rodent model) at a single dose level. The results are positive and internally consistent with traditional use, but the complete absence of human data means that translation to clinical efficacy and safety in humans cannot be assumed.

A 2026 biochemical study also reported anti-inflammatory activity from leaf extracts measured using the protein denaturation inhibition assay. The methanolic extract showed the greatest phenolic and flavonoid content and exhibited significant anti-inflammatory activity, with a protein denaturation IC50 of 12.81 µg/mL. This is an in vitro assay and its correlation with in vivo human anti-inflammatory effects is uncertain.

4.2 Antioxidant Activity

The methanolic extract of P. capensis showed significant effect on hydrogen peroxide radical scavenging activity and less significant effect on nitric oxide radical scavenging activity when compared with the standard.

More precisely quantified antioxidant data were generated in the 2026 Chemistry & Biodiversity study: the methanolic extract exhibited strong antioxidant activity with DPPH IC50 = 14.85 µg/mL and ABTS IC50 = 26.13 µg/mL.

A 2025 Springer Nature study on P. capensis-mediated zinc oxide nanoparticles (ZnO NPs) also measured antioxidant capacity: the ZnO NPs exhibited notable antioxidant activity, with an IC50 value of 105.61 µg/mL for ABTS and 101.89 µg/mL for DPPH assays.

Evidence strength: All antioxidant data are in vitro radical scavenging assays. Such assays do not directly predict in vivo antioxidant efficacy. No animal or human antioxidant studies are available.

4.3 Antimicrobial Activity

Antimicrobial activity has been investigated across multiple extract types. The chloroform extract of the stem showed moderate activity against bacterial organisms including Staphylococcus aureus, Bacillus subtilis, and Escherichia coli. The chloroform extract of the whole plant showed no antifungal activity at concentrations of 100 mg/mL and 300 mg/mL against fungal organisms tested.

In the 2026 Chemistry & Biodiversity study, the methanolic leaf extract was specifically quantified: it exhibited notable antibacterial efficacy against Staphylococcus aureus, producing a zone of inhibition of 22 ± 0.3 mm with an MIC of 24 µg/mL.

The green synthesis study (Springer, 2025) reported that antibacterial studies of P. capensis-mediated ZnO NPs demonstrated significant inhibition of Staphylococcus aureus, with a 25 mm zone of inhibition at 75 µg/mL.

Evidence strength: All data are from in vitro disc diffusion and MIC assays. Results show consistent activity against S. aureus, though the antifungal picture is mixed, with one study reporting an absence of activity. No clinical or animal infection studies have been published.

4.4 Cytotoxic and Anticancer Activity

Anticancer research on P. capensis is in an early, purely preclinical stage. The most detailed investigation appeared in a 2026 study in Chemistry & Biodiversity. The methanolic extract demonstrated the highest cytotoxicity against HT-29 colon cancer cells with an IC50 of 65.62 µg/mL.

In parallel, the 2025 ZnO NP study (Springer) reported: cytotoxicity analysis against the HT-29 colon cancer cell line using the MTT assay yielded an IC50 value of 95.37 µg/mL for the plant-mediated nanoparticles.

The 2026 Chemistry & Biodiversity study also used computational methods to investigate potential mechanisms. Molecular docking revealed strong binding affinities of major constituents, particularly octadecanedioic acid, cyclohexane derivatives, and n-octacosanol, toward the colorectal cancer target DCAF1/VprBP (3WA0); further validation through a 100 ns molecular dynamics simulation and MM-PBSA analysis confirmed stable binding with minimal RMSD fluctuations; overall, these findings highlight the therapeutic potential of P. capensis and support its further in vivo evaluation for cancer treatment.

Evidence strength: All anticancer evidence consists of in vitro cell-line cytotoxicity data and in silico docking studies. These are hypothesis-generating findings only. No animal tumor models or human oncology studies of any kind exist. The authors themselves explicitly note that in vivo evaluation is required.

4.5 Anti-Inflammatory Activity — ZnO Nanoparticle Platform

In terms of anti-inflammatory potential of P. capensis-mediated ZnO NPs, the IC50 values were determined to be 79.86 µg/mL for HRBC membrane stabilization and 83.74 µg/mL for albumin denaturation inhibition. These findings contribute to the characterization of the plant extract's utility as a biogenic reducing and capping agent in nanoparticle synthesis, while also confirming bioactive residuals from the plant material persist in the final formulation.

5. Body Systems and Health Areas Associated with Pentatropis capensis

Musculoskeletal and pain pathways: Taking warm leaf juice as nasal drops to alleviate headache, running nose, and body ache is one of the popular ethnomedicinal uses; P. capensis is popular among folklore remedies for various injuries and inflammatory problems.
Skin and dermatology: The whole plant is traditionally used as an antifungal, antiseptic, coolant, and in the treatment of various skin ailments. Classical Ayurvedic applications include Kustha (skin diseases) and Shvitra (vitiligo).
Respiratory system: It has been used in the management of respiratory congestion. Leaf-based preparations applied intranasally represent one of the oldest documented delivery routes in this tradition.
Neurological / epilepsy: Ethnobotanical records indicate application in epilepsy (Apasmara).
Gynaecological / reproductive: Ethnobotanical records indicate application in gynecological disorders. The Ashtanga Hridaya describes its use in treating Guhya Roga (genital disorders).
Haematological: Classical Ayurvedic sources associate the plant with Raktavikara (blood disorders) among its areas of application.
Oncology (preclinical only): In vitro, the methanolic extract demonstrated the highest cytotoxicity against HT-29 colon cancer cells (IC50 = 65.62 µg/mL). No clinical relevance has been established.
Antimicrobial / infectious disease: Bacteriostatic activity against S. aureus, B. subtilis, and E. coli has been shown in vitro; antifungal activity was not detected in one whole-plant study.
Rejuvenation / rasayana: Ayurvedic lexicons highlight its properties as a rasayana (rejuvenator) and balya (strength promoter).

6. Dosage Forms and Reported Dosages

No standardized dosage recommendations have been published by any regulatory body, pharmacopeia, or major evidence-based database for P. capensis. The following dosages are reported exclusively as used in experimental studies or in traditional descriptions recorded in academic literature, not as clinical recommendations.

6.1 Animal Study Dosage

The single published animal pharmacology study (PMC 2014) used oral administration in rats. The aqueous extract of P. capensis leaves showed significant (P < 0.001) analgesic effects at dose levels of 450 mg/kg, administered orally. The use of a single dose level is a methodological limitation of this study, as no dose-response relationship was established.

6.2 In Vitro Concentrations

Antioxidant (DPPH): methanolic extract IC50 = 14.85 µg/mL.
Antioxidant (ABTS): methanolic extract IC50 = 26.13 µg/mL.
Anti-inflammatory (protein denaturation inhibition): methanolic extract IC50 = 12.81 µg/mL.
Antibacterial MIC against S. aureus: 24 µg/mL.
Cytotoxicity against HT-29 (colon cancer): methanolic extract IC50 = 65.62 µg/mL.
ZnO NP cytotoxicity against HT-29: IC50 = 95.37 µg/mL by MTT assay.
ZnO NP antioxidant (ABTS): IC50 = 105.61 µg/mL.

These are laboratory values derived from biochemical and cell-culture assays; they do not represent or predict human therapeutic doses.

6.3 Traditional / Ethnomedicinal Preparations (Non-Quantified)

Traditional use includes taking warm leaf juice as nasal drops; leaves are boiled with coconut oil for external application to cuts and wounds. Classical Ayurvedic compound formulations incorporate the plant as one of multiple ingredients; individual-herb quantities within such polyherbal recipes are not standardized across sources and vary by classical text and practitioner tradition.

7. Safety Considerations

P. capensis has not been evaluated in any published formal toxicology study (acute, subchronic, or chronic) specifically designed for this species. No safety data from human clinical studies or observational reports exist in the indexed literature. The following safety-relevant facts are drawn from verified scientific sources.

7.1 Family-Level Chemical Safety Considerations

Members of the Asclepiadoideae subfamily (within Apocynaceae) possess many bioactive constituents including cyanogenetic glycosides, a chemical class that can release hydrogen cyanide upon hydrolysis. While cyanogenetic glycosides are reported as a constituent class for the broader taxon, their specific presence, concentration, and toxicological relevance in P. capensis preparations has not been formally quantified or risk-assessed in the published literature.

7.2 Evidence Gap

P. capensis is traditionally used to treat various ailments; however, it lacks systematic scientific validation. The absence of formal toxicity studies — including genotoxicity, reproductive toxicity, and organ-specific toxicity assessment — means that the safety profile of the plant or its extracts cannot be characterized beyond the observation that in vivo animal analgesic/anti-inflammatory testing at 450 mg/kg oral in rats did not report acute mortality or obvious gross toxicity, though this single study was not a dedicated safety study and did not systematically evaluate adverse outcomes.

7.3 Traditional Use Signals

Classical Ayurvedic texts describe one of the plant's properties as emetic. Ayurvedic lexicons highlight its properties as an emetic, indicating that at certain doses or preparations, the plant can induce vomiting. This traditional signal is consistent with the irritant or saponin-rich phytochemical character of many Asclepiadoideae members and should be considered in evaluating dose-appropriate preparations.

7.4 Interactions

No published studies have examined pharmacokinetic or pharmacodynamic interactions between P. capensis constituents and pharmaceutical drugs, herbal preparations, or food components. The presence of salicylic acid among the identified constituents is chemically noteworthy (salicylates are known to interact with anticoagulants, non-steroidal anti-inflammatory drugs, and some antidiabetic agents in clinical contexts), but no interaction data specific to P. capensis exist in the peer-reviewed literature.

7.5 Regulatory Status

The plant is described as an "extra pharmacopoeial" drug — meaning it has not been formally monographed or standardized in any major contemporary pharmacopeia (British Pharmacopoeia, Indian Pharmacopoeia, USP, European Pharmacopoeia, or WHO monograph series). Pharmacognostic work has been conducted specifically to highlight its botanical parameters and establish microscopic standards to authenticate the crude drug, representing early-stage quality standardization work rather than a regulatory approval pathway.

8. Overall Evidence Assessment

Pentatropis capensis is an ethnomedicinally significant plant with an extensive record of use in South Asian traditional medicine, particularly the Ayurvedic and Siddha systems. Its chemical profile is broadly consistent with its traditional applications — the presence of salicylic acid, β-sitosterol, α-amyrin (anti-inflammatory triterpene), phenolics, and flavonoids (antioxidant) provides plausible phytochemical underpinning for some historical indications. However, pharmacological evaluations of P. capensis and related species have revealed significant antioxidant, analgesic, anti-inflammatory, and antimicrobial properties, supporting its traditional therapeutic use, yet these evaluations remain entirely preclinical. No human trials of any phase, and no systematic reviews, exist for this species. Pharmacognostic standardization — necessary for quality control of botanical ingredients — has been initiated but the plant remains extra-pharmacopoeial. Investigators have consistently called for further in vivo and ultimately clinical studies to validate the promising early-stage signals.

References

Health Conditions

Health conditions that Pentatropis capensis may help support.

No conditions available.

Body Systems

Body systems that Pentatropis capensis may help support.

No body systems available.